A method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology
Through capillary electrophoresis technology and automated processing system, hybridization probes are designed and RNA hydrolase cleavage and high-temperature denaturation and dissociation are solved, and the problems of high requirements for mRNA capping rate detection equipment in the existing technology and difficulty in sample quality control in batches are achieved. It has efficient and economical batch testing, and is suitable for the quality verification of mRNA drugs industrialization.
Patent Information
- Application Number
- CN202310642481.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-01
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2043-06-01
AI Technical Summary
The existing mRNA capping rate detection methods have problems such as high equipment requirements, limited scope of application, and difficult to control the quality of batch samples between batches, and lack of automated batch detection technology.
Using capillary electrophoresis technology, hybridization probes are designed according to the 5'UTR region sequence of the mRNA to be tested, and mRNA capping is achieved through directed cleavage and high-temperature denaturation and dissociation through RNA hydrolase, combined with an automated nucleic acid sample processing system and high-resolution capillary electrophoresis equipment. Automatic batch quantitative detection of rate.
It realizes efficient, economical and high resolution mRNA capping rate detection, simple operation, low cost of consumables, accurate and repeatable experimental results, and is suitable for quality verification in mRNA drug industrialization.
Smart Images

Figure CN116640833B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biological detection technology, and in particular to a method for automatically batch detecting mRNA capping rates by using capillary electrophoresis technology. Background Art
[0002] As a transient carrier of genetic information, mRNA can use cellular machinery to synthesize proteins. Because of its safety, power, speed, flexibility, and programmable production characteristics, it has excellent potential in drug research and development. Therefore, mRNA drugs are very attractive as a new type of nucleic acid drugs, and the related demand is also increasing.
[0003] The most critical step in the preparation of mRNA drugs is to produce a structurally complete and biologically active mRNA stock solution. In vitro synthesized mRNA needs to have a complete structure to exert normal biological functions. The smallest mRNA structure usually contains a 5' cap, a 5' / 3' untranslated region (UTR), an open reading frame (ORF) encoding a protein, and a 3' Poly A tail. The structure of the mRNA transcribed by eukaryotic RNA polymerase II that is co-transcriptionally modified at its 5' end is called a cap. The cap structure is crucial for mRNA: ① The mRNA cap promotes the effective translation of mRNA by recruiting translation initiation factors; ② The cap structure can protect mRNA from rapid degradation by nucleases, thereby effectively maintaining the relative stability of mRNA; ③ For drug development, mRNA lacking a cap structure will be recognized as "foreign" by the innate immune sensor pattern recognition receptor (PRR) in the body, thereby triggering excessive activation of the innate immune response and degradation of mRNA.
[0004] In recent years, based on species diversity and with the deepening of basic research, more cap structures have been discovered. In addition to the most common m7GPPPN cap structure in eukaryotes, 2,2,7-m3GPPPN, 5'-γ-mPPPN, mGpppN, GpppN, GpppmNm, m7G(5')ppp(5')m62AmpAmpCmpm3Um(Cap4), etc., as well as the nicotinamide adenine dinucleotide (NAD) cap originally discovered in bacteria and yeast have also been identified in mammalian cells. In addition, cap analogs such as m7G(5')ppp(5')(2'OMeA)pG, m7(3'OMeG)(5')ppp(5')(2'OMeA)pG, m7G(5')ppp(5')(2'OMe,m6A)pG, etc., as well as mRNA co-transcriptional cap analogs based on positive-strand RNA viruses have been developed on the market for co-transcriptional capping of mRNA.
[0005] m7G(5')ppp(5')(2'OMeA)pU. Due to the increase in the types of existing cap structures and the increase in the demand for batch detection of mRNA capping rates, it is urgent to develop technical methods for batch detection of mRNA capping rates. At present, the methods for determining the types of mRNA caps and capping efficiency mainly include: ELISA method (for example, Chinese patent application CN105209633A uses anti-m7G specific antibodies to bind to the cap structure, and uses secondary antibodies to bind to primary antibodies to quantitatively detect RNA capping efficiency using ELISA. This method requires specific reagents to make a standard curve, and the applicable cap structures are limited. Due to different samples, there are easy differences in batch accuracy), HPLC chromatography (for example, Chinese patent application CN105051213A, this method requires the use of appropriate chromatographic columns, has high requirements for capped and uncapped samples, and the cap structures need to be greatly different to easily separate the capped and uncapped sample peaks from the chromatogram), ImageJ software analysis method (for example, Chinese patent application CN112626177A uses ImageJ software to analyze the gel run map to quickly and quantitatively detect RNA capping efficiency. This method can only quantitatively analyze samples with obvious differences in the amount of mRNA capped and uncapped samples, and is not suitable for volume The detection effect of mRNA samples with high capping rates obtained by external transcription is limited), HPLC tandem mass spectrometry (for example, Chinese patent application CN112111558A uses HPLC-MS to determine the activity of vaccinia virus capping enzyme. This method can accurately analyze the capping rate of samples with the help of mass spectrometry, but the equipment requirements are high, and the method is limited to the analysis of the capping rate of enzymatic capping), time-of-flight mass spectrometry technology (for example, Chinese patent application CN114250268A uses time-of-flight mass spectrometry technology to quickly detect the capping efficiency of mRNA. This method has high equipment requirements, and the capped and uncapped sequences used are limited, and it is only used for the capping rate detection of fixed sequence mRNA, and the scope of application is limited), RT-qPCR method (for example, patent CN114395613B provides a method for detecting the activity of vaccinia virus capping enzyme in vitro using RT-qPCR, and the activity of vaccinia virus capping enzyme is determined by detecting the difference in CT values. However, this method is only applicable to enzymatic capping detection), etc. In addition, existing detection methods are mostly manual operations, and there is no automated processing or batch processing method for mRNA samples. There may be large differences between batches of samples manually operated, making it difficult to achieve the standard requirements for controllability of batch sample quality.
[0006] Capillary electrophoresis (CE) technology is a method for separating and analyzing biomolecules (nucleic acids, proteins, peptides, sugars, etc.) based on differences in charge and molecular weight. It uses an electric field to move charged biomolecules in a charged capillary to separate molecules of different sizes, charges, and shapes. mRNA is a single-stranded biomacromolecule composed of nucleotides and has a negative charge. Since nucleic acid mRNA has a negative charge, it can move and be differentially separated in the capillary under the action of an electric field based on the size, morphology, and charge density of mRNA. The specific process of mRNA separation involves many factors, including the pH value of the buffer, the ion concentration and type, the type and size of the capillary material, and so on. In practical applications, it needs to be adjusted and optimized according to different samples and experimental purposes. By optimizing the experimental conditions, efficient and high-resolution separation and quantification of nucleic acid samples can be achieved. In short, capillary electrophoresis technology is widely used in biomedicine, molecular biology, food science and other fields.
[0007] Chinese patent application CN115678968A discloses a method for detecting mRNA capping efficiency using capillary electrophoresis. The patent adopts a manual operation method, which is mainly used to detect the m7GPPPN cap structure, and the detection object is relatively single; the selected site of the probe designed in the patent is the nucleotides in the 10th to 85th region of the 5' end of the 5'UTR, and the probe design is not designed from scratch, so the optional sequence interval of the probe is limited; since the probe designed from scratch will also appear in the capillary electrophoresis, the electrophoresis peaks of the uncapped sequence and the capped sequence are more difficult to distinguish, so a detection method technology with better resolution is needed, however, the result peak graph obtained by the patent based on its method is not independent but sticky together, which will affect the accuracy of the calculation of the capping rate detection result; after the DNA probe designed in the patent is combined with the test mRNA, it needs to be enzymatically hydrolyzed twice, that is, DNase enzymatic hydrolysis is required after RNase enzymatic hydrolysis.
[0008] Therefore, developing a set of simple, economical, efficient, batch, high-resolution automated processing methods for detecting mRNA capping efficiency is one of the urgent issues to be addressed in mRNA drug research and drug production quality inspection. Summary of the invention
[0009] The object of the present invention is to provide a method for automatically batch detecting mRNA capping rate by using capillary electrophoresis technology.
[0010] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:
[0011] The present invention provides a method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology, comprising the following steps:
[0012] (1) Designing a hybridization probe based on the 5'UTR sequence of the mRNA to be detected;
[0013] (2) denaturing and annealing the hybridization probe and the mRNA to be detected to obtain a hybrid sequence;
[0014] (3) Directedly cleaving the hybrid sequence using RNA hydrolase, purifying it and then denaturing and dissociating it at high temperature to obtain a mixture containing the probe, capped mRNA and uncapped mRNA;
[0015] (4) The mixture extracted in step (3) is subjected to capillary electrophoresis, and the capping rate of the mRNA to be tested is calculated based on the capillary electrophoresis result.
[0016] Preferably, the hybridization probe is reverse complementary to the mRNA to be detected.
[0017] Preferably, the hybridization probe is designed based on the base sequence in the 1st to 100th region from the 5' end of the 5'UTR region sequence of the mRNA to be detected.
[0018] Preferably, the length of the hybridization probe is ≥15 nt.
[0019] Preferably, the cap structure of the mRNA to be tested includes: a natural mRNA 5' end cap structure, and an artificially synthesized mRNA 5' end cap structure analog with modified or unmodified mRNA.
[0020] Preferably, in step (2), the ratio of the added mRNA to be detected to the hybridization probe is 1:1 to 1:5.
[0021] Preferably, the denaturation conditions in step (2) are: denaturation at 90-100° C. for 1-10 minutes, and the annealing is: annealing at 70° C. and cooling to room temperature in a cycle of -10° C. / 2 minutes.
[0022] Preferably, the RNA hydrolase in step (3) is one of RNase H, RNase HI and RNase HI.
[0023] Preferably, the temperature of the high temperature denaturation and dissociation in step (3) is 70 to 100° C., and the time is 2 to 10 minutes.
[0024] Preferably, the length of the capillary in step (4) is 10 to 60 cm.
[0025] Preferably, the capillary electrophoresis in step (4) further comprises a reverse electrophoresis procedure, the reverse electrophoresis time is 10 to 60 minutes, and the gel is stored at a temperature of 2 to 8°C during electrophoresis.
[0026] The present invention designs a hybridization probe according to the 5'UTR region sequence of the mRNA to be tested, and then hybridizes the hybridization probe with the mRNA to be tested to obtain a hybrid sequence, and enzymatically hydrolyzes, purifies and denatures the hybrid sequence at high temperature to obtain a probe, a capped mRNA sequence and an uncapped mRNA sequence. The mRNA capping rate is analyzed by using an automated nucleic acid sample processing system and a capillary electrophoresis device with good sensitivity, high resolution and high accuracy. By setting a reverse electrophoresis program and a specific gel pouring and gel storage program, the automated batch quantitative detection of the mRNA capping rate can be achieved, and once the program is set, it can run stably without complicated operations. In addition, the capillary gel is stored at 2 to 8°C, and the stability of the gel properties can be maintained within 24 hours. The editing program is repeated at intervals to balance and pour gel, and a stable batch detection result of the mRNA capping rate can be obtained.
[0027] The characteristic peak baseline of the capillary electrophoresis spectrum obtained by the method of the present invention is smooth, the signal-to-noise ratio is high, and although the molecular weights of the capped and uncapped samples are similar, the separation between the signal peaks of the two is high. For multiple mRNA capped samples, through a single gel filling, adding a reverse electrophoresis program, multiple injections and electrophoresis can be performed, thereby obtaining the capping rate detection results of multiple samples and realizing batch detection. The present invention is simple to operate, has low consumables cost, and has accurate and repeatable experimental results, and is very suitable for quality inspection in the industrialization of mRNA drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 This is the capillary electrophoresis diagram of the enzyme-cut and capped (G) probe in Example 3;
[0029] Figure 2 is the capillary electrophoresis diagram of the capped (G) sample in Example 3;
[0030] Figure 3 is the capillary electrophoresis diagram of the sample without capping (G) in Example 3;
[0031] Figure 4 The capillary electrophoresis diagram of the mixed sample with capping (G) and without capping (G) in Example 3;
[0032] Figure 5 is the capillary electrophoresis diagram of the capped (U) sample in Example 3;
[0033] Figure 6 This is the capillary electrophoresis diagram of the internal reference markers (20nt, 50nt, 70nt and 100nt) in Example 3. DETAILED DESCRIPTION
[0034] The present invention provides a method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology, comprising the following steps:
[0035] (1) Designing a hybridization probe based on the 5'UTR sequence of the mRNA to be detected;
[0036] (2) denaturing and annealing the hybridization probe and the mRNA to be detected to obtain a hybrid sequence;
[0037] (3) Directedly cleaving the hybrid sequence using RNA hydrolase, purifying it and then denaturing and dissociating it at high temperature to obtain a mixture containing the probe, capped mRNA and uncapped mRNA;
[0038] (4) The mixture obtained in step (3) is subjected to capillary electrophoresis, and the capping rate of the mRNA to be tested is calculated based on the capillary electrophoresis result.
[0039] In the present invention, the hybridization probe is reverse complementary to the mRNA to be detected.
[0040] In the present invention, the hybridization probe is designed based on the base sequence in the 1st to 100th region from the 5' end of the 5'UTR region sequence of the mRNA to be detected, and the length of the hybridization probe is ≥15nt.
[0041] In the present invention, the hybridization probe is preferably also coupled with biotin for coupling with streptavidin magnetic beads for purification.
[0042] In the present invention, the cap structure of the mRNA to be tested includes: the natural mRNA 5' end cap structure, the artificially synthesized mRNA 5' end cap structure analogs with modified or unmodified ends, preferably, G, U, A, C caps and their N nucleotide analogs (N≥1).
[0043] In the present invention, the ratio of the added mRNA to be detected and the hybridization probe in step (2) is 1:1 to 1:5.
[0044] In the present invention, the denaturation conditions in step (2) are: denaturation at 90-100°C for 1-10 minutes, preferably at 95°C for 5 minutes.
[0045] In the present invention, the annealing in step (2) is: annealing at 70°C, and cyclically dropping from -10°C / 2 minutes to room temperature.
[0046] In the present invention, the RNA hydrolase in step (3) is one of RNase H, RNase HI and RNase HII, preferably RNase H.
[0047] In the present invention, the temperature of RNA hydrolase digestion reaction is 35-40° C., and the time is 1-4 hours, preferably, 37° C., for 3 hours.
[0048] In the present invention, the temperature of the high temperature denaturation and dissociation in step (3) is 70-100°C, and the time is 2-10 minutes, preferably 80°C, 3 minutes.
[0049] In the present invention, the processes of steps (2) and (3) are performed on an automatic nucleic acid extractor, which is a Thermo Scientific KingFisherApex nucleic acid purification system or a Roche MagNAPure LC fully automatic nucleic acid purification and sample loading system, preferably a Thermo Scientific KingFisherApex nucleic acid purification system.
[0050] In the present invention, the length of the capillary in step (4) is 10 to 60 cm.
[0051] In the present invention, the time of the capillary electrophoresis in step (4) is 50 to 70 minutes, preferably 60 minutes.
[0052] In the present invention, the capillary electrophoresis in step (4) further comprises a step of adding reverse electrophoresis for 10 to 60 minutes, preferably 20 minutes, after the electrophoresis of each sample needle is completed.
[0053] In the present invention, when performing the capillary electrophoresis in step (4), it is also necessary to add a nucleic acid internal standard electrophoresis.
[0054] In the present invention, the process of step (4) is performed on a capillary electrophoresis device, and the capillary electrophoresis device is: BECKMAN PA800 or SCIEX PA800plus.
[0055] In the present invention, the capillary electrophoresis in step (4) also includes the step of enzyme-cleaved probe electrophoresis, which can be used to detect whether the designed probe has self-cleavage, because probe self-cleavage affects the accuracy of the results.
[0056] In the present invention, the storage temperature of the gel used for capillary electrophoresis in step (4) is 2-8° C., which can maintain the stability of the gel properties within 24 hours. The editing program repeats the balancing and gel filling at intervals to obtain stable mRNA capping rate batch detection results.
[0057] In the present invention, the mRNA capping rate detection method can be widely used in basic biological research, clinical diagnosis, drug development and mRNA quality control in drug production.
[0058] The technical solutions provided by the present invention are described in detail below in conjunction with the embodiments, but they should not be construed as limiting the protection scope of the present invention.
[0059] Example 1
[0060] In this example, uncapped firefly luciferase (Fluc) mRNA and capped Fluc mRNA were used as detection objects. Uncapped and capped Fluc mRNA samples were prepared by in vitro transcription using the co-transcription method.
[0061] The in vitro transcription reaction and the preparation of mRNA capping detection samples must be carried out in a completely DNase / RNase-free environment, and unless otherwise specified, the consumables, reagents, buffers, etc. involved must be nuclease-free.
[0062] (1) Preparation of conventional codon-optimized uncapped Fluc mRNA samples by in vitro transcription
[0063] The linearized DNA plasmid containing the Fluc gene sequence was used as a transcription template after enzyme removal and purification, and the commercially available T7 in vitro transcription kit was used for transcription synthesis. The reaction system is shown in Table 1.
[0064] Table 1 Uncapped mRNA in vitro transcription system
[0065] Components 20μL reaction system (μL) DNase / RNase-Free Water 6 GTP (100 mM) 2 ATP(100mM) 2 UTP1 (100 mM) 2 CTP1 (100 mM) 2 10X Transcription Buffer 2 DNA template (2 μg) 1000 ng / μL 2 T7RNA Polymerase Mix 2 Total volume 20
[0066] According to the above system, each component was added to an enzyme-free 200 μL PCR tube, mixed and centrifuged, and then placed on a PCR instrument for reaction at 37°C for 2 hours. After the transcription reaction was completed, 2U DNase I was added to each system and continued to react at 37°C for 15 minutes to remove the template DNA. The integrity of the synthesized mRNA was detected by denaturing agarose gel electrophoresis. After the test was qualified, the uncapped mRNA sample was purified and the concentration of the mRNA was detected using a micro-ultraviolet spectrophotometer. The conventional codon-optimized firefly luciferase uncapped Fluc mRNA sequence is shown in SEQ ID NO.1.
[0067] (2) Preparation of conventional and replicative codon-optimized capped Fluc mRNA samples by in vitro transcription
[0068] The linearized DNA plasmid containing the Fluc gene sequence was used as a transcription template after enzyme removal and purification, and a commercially available T7 in vitro transcription kit was used for transcription synthesis. The reaction system was shown in Table 2. The cap analogs were commercially available m7(3'OMeG)(5')ppp(5')(2'OMeA)pG (G cap, hereinafter referred to as G) or m7G(5')ppp(5')(2'OMeA)pU (U cap, hereinafter referred to as U) for preparing conventional codon-optimized Fluc capping samples and replicative codon-optimized Fluc capping samples according to conventional and replicative templates. The uncapped Fluc mRNA sequence of replicative codon-optimized is shown in SEQ ID NO.2.
[0069] Table 2 Capped mRNA in vitro transcription system
[0070] Components 20μL reaction system (μL) DNase / RNase-Free Water 4.4 GTP (100 mM) 2 ATP(100mM) 2 UTP1 (100 mM) 2 CTP1 (100 mM) 2 G cap / U cap (100mM) 1.6 10X Transcription Buffer 2 DNA template (2 μg) 1000 ng / μL 2 T7RNA Polymerase Mix 2 Total volume 20
[0071] According to the above system, each component was added to a 200 μL PCR tube without enzyme, mixed and centrifuged, and then placed on a PCR instrument for reaction at 37°C for 2 hours. After the transcription reaction was completed, 2U DNase I was added to each system and continued to react at 37°C for 15 minutes to remove the template DNA. The integrity of the synthesized mRNA was detected by denaturing agarose gel electrophoresis. After the test was qualified, the capped mRNA sample was obtained after purification, and the concentration of mRNA was detected using a micro-ultraviolet spectrophotometer.
[0072] Example 2
[0073] Prepare samples for mRNA capping rate detection.
[0074] The mRNA used for sample preparation for capillary electrophoresis was the uncapped mRNA sample prepared in Example 1 and two capped mRNA samples. Shanghai Biotech Co., Ltd. was commissioned to synthesize two hybridization probes and couple them with biotin:
[0075] Probe G (SEQ ID NO: 3): AATACTAGUUUAUUCUCCCU / 3BioTEG /
[0076] Probe U (SEQ ID NO: 4): AAAATCUUUUGGCGUCGUGU / 3BioTEG /
[0077] The mRNA synthesized in Example 1 was denatured and annealed with the respective probes according to the system in Table 3. The reaction program of the automated sample processing is shown in Table 4.
[0078] Table 3 Denaturation and annealing of mRNA and probe
[0079]
[0080] After the above components are added, mix and centrifuge.
[0081] The mixed samples in Table 3 were transferred to a 96-well deep-well plate, placed on the operating tray of the Thermo Scientific KingFisherApex nucleic acid purification system, and the automated mRNA sample processing program was set according to Table 4 (magnetic beads were added during the processing to purify the hybrid fragments of the probe and mRNA).
[0082] Table 4 Automated mRNA sample processing procedures
[0083]
[0084]
[0085] Through the above procedures, the purification of the mRNA capping rate detection sample is completed, and the sample can be detected by capillary electrophoresis after it cools to room temperature.
[0086] Example 3
[0087] This example uses a capillary electrophoresis device to detect the capping rate of mRNA. The samples used are the samples obtained in Example 2: uncapped (G) samples, capped (G) samples, samples of equal mass of uncapped (G) and capped (G) samples, and capped (U) samples. The sample volume is adjusted to 20 μL with enzyme-free water, and then the sample can be tested on the machine.
[0088] The conditions used for capillary electrophoresis are: capillary length of 60 cm, temperature of capillary electrophoresis of 30°C, electrophoresis voltage of 30 kV, UV light collection wavelength of 254 nm, injection time of 15 seconds. The storage temperature of gel is 8°C. The program sequence is set as shown in Table 5.
[0089] Table 5 Automated mRNA (G) capping rate detection program
[0090]
[0091]
[0092] In order to detect whether there is a self-cleavage site in the probe, which affects the reaction efficiency of the probe, it is necessary to add a separate enzyme-cleaved probe and run capillary electrophoresis during the first test. This example uses the enzyme-cleaved probe G capillary electrophoresis as a demonstration (Table 5, No. 1), and the results are shown in Figure 1 .like Figure 1 The capillary electrophoresis diagram of the enzyme-cut probe G is shown. The probe is a single peak, indicating that the probe screened using computer-assisted screening has no self-cleavage site and theoretically has good hybridization performance, which is suitable for the detection of mRNA capping rate.
[0093] In the in vitro co-transcription capping reaction, due to the competitive relationship between the cap structure and nucleotide G and the difference in capping efficiency, there will be capped mRNA and uncapped mRNA in the reaction system. After directional enzyme digestion with RNase H, the mRNA fragments complementary to the probe hybridization region can be specifically captured by magnetic beads through the biotin label on the probe. After high-temperature denaturation, the mRNA fragments (including capped and uncapped mRNA fragments) and the probe in the complementary region of the probe will dissociate in the solution. After capillary electrophoresis, the electrophoresis speed of each fragment will be different, so that each fragment can be distinguished on the capillary electrophoresis diagram. The capping rate can be calculated by the peak area ratio of capped mRNA to total mRNA (including capped mRNA and uncapped mRNA).
[0094] The peak area ratio of each peak was obtained by software calculation ( Figure 2 , Table 7), according to the values in Table 7, the capping rate of the mRNA capped (G) sample is 4.71 / (0.93+4.71)*100%=83.51%.
[0095] Table 7 Peak area ratio of each peak of mRNA capped (G) and uncapped samples
[0096] PK# Name Time Corrected Area Corrected Area Percent 1 Probe 42.48 5432.78 94.36 2 Uncapped peaks in the sample 44.65 53.73 0.93 3 Capped peaks in the sample 44.92 271.10 4.71
[0097] Figure 3 For the uncapped (G) sample using capillary electrophoresis, the sample contains only the probe peak and the uncapped (G) sample peak.
[0098] Figure 4 The capillary electrophoresis diagram of the mixed sample of capped (G) and uncapped (G) is shown in the figure. The peak positions of the probe, uncapped (G) and capped (G) are marked. Figure 4 Peak shapes of probe, uncapped (G), and capped (G) in mixed samples Figure 2 The peak shape of the capped (G) sample run alone was consistent.
[0099] Figure 5 is the capillary electrophoresis diagram of the capped (U) sample. The peak area ratio of each peak is calculated by software (Table 8), and the U cap ( Figure 5 ) has a capping rate of 27.46 / (7.49+27.46)*100%=78.57%.
[0100] Table 8 Peak area ratio of each peak of mRNA capped (U) and uncapped samples
[0101] PK# Name Time Corrected Area Corrected Area Percent 1 Probe 41.88 3311.46 65.05 2 Uncapped peaks in the sample 44.55 381.27 7.49 3 Capped peaks in the sample 44.70 1398.15 27.46
[0102] In addition, by adding internal reference markers (20nt, 50nt, 70nt and 100nt) ( Figure 6) can monitor the stability of instruments, accessories and programs, and can accurately analyze the molecular weight of samples using internal standards and the software's own functions. Therefore, the present invention is a method that is very suitable for batch detection of mRNA capping rates.
[0103] In Example 3, the baselines of the characteristic peaks of each spectrum are smooth, and the signal-to-noise ratio is high. Although the molecular weights of the capped and uncapped samples are similar, the separation between the signal peaks of the two is high. Therefore, the present invention can design a synthetic probe according to the sequence of the mRNA to be tested, and protect the mRNA from degradation by RNA hydrolases by hybridization between the mRNA to be tested and the probe. After purification and high-temperature denaturation, the sequence containing the cap structure region at the 5' end of the mRNA is obtained. The mRNA capping rate is analyzed using an automated nucleic acid sample processing system and a capillary electrophoresis device with good sensitivity, high resolution, and high accuracy. By setting a reverse electrophoresis program, as well as a specific gel pouring and gel preservation program, the automated batch quantitative detection of the mRNA capping rate can be achieved, and once the program is set, it can run stably without complicated operations. The method of the present invention is simple to operate, has low consumables cost, and the experimental results are accurate and repeatable, and is very suitable for quality inspection in the industrialization of mRNA drugs.
[0104] The above is only a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principle of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. A method for automatically batch detecting mRNA capping rate using capillary electrophoresis technology, characterized in that: The steps include: (1) Design a hybridization probe based on the 5'UTR sequence of the mRNA to be detected; (2) denaturing and annealing the hybridization probe and the mRNA to be detected to obtain a hybrid sequence; (3) Directedly cleaving the hybrid sequence using RNA hydrolase, purifying it and then denaturing and dissociating it at high temperature to obtain a mixture containing the probe, capped mRNA and uncapped mRNA; The purification method comprises: coupling biotin to the hybridization probe designed in step (1); coupling magnetic beads with streptavidin to the biotin on the hybridization probe based on the principle of coupling biotin and streptavidin during purification; capturing the hybridization probe with streptavidin magnetic beads, and then completing the purification of the mRNA to be detected on the hybridization probe; (4) subjecting the mixture extracted in step (3) to capillary electrophoresis, and calculating the capping rate of the mRNA to be tested based on the capillary electrophoresis results; The capillary electrophoresis in step (4) also includes a step of adding reverse electrophoresis for 10 to 60 minutes after the electrophoresis of each sample needle is completed.
2. The method according to claim 1, characterized in that The hybridization probe is reverse complementary to the mRNA to be detected; the hybridization probe is designed based on the base sequence in the 1st to 100th region from the 5' end of the 5'UTR region sequence of the mRNA to be detected; the length of the hybridization probe is ≥15 nt.
3. The method according to claim 1, characterized in that: The cap structure of the mRNA to be tested includes: a natural mRNA 5' end cap structure, and an artificially synthesized mRNA 5' end cap structure analog with modified or unmodified mRNA.
4. The method according to claim 1, characterized in that: In step (2), the ratio of the mRNA to be detected to the hybridization probe is 1:1 to 1:
5.
5. The method according to claim 1, characterized in that: The denaturation conditions in step (2) are: 90-100°C for 1-10 minutes, and the annealing conditions are: 70°C annealing, -10°C / 2 minutes cycle down to room temperature.
6. The method according to claim 1, characterized in that: The RNA hydrolase in step (3) is one of RNase H, RNase HI and RNase HII.
7. The method according to claim 1, characterized in that: The temperature of the high temperature denaturation dissociation in step (3) is 70-100°C and the time is 2-10 minutes.
8. The method according to claim 1, characterized in that: The length of the capillary in step (4) is 10 to 60 cm.
9. The method according to claim 1, characterized in that: During step (4) electrophoresis, the gel is stored at a temperature of 2 to 8°C.
Citation Information
Patent Citations
Quantitative assessment for cap efficiency of messenger RNA
CN105051213A
Quantitative assessment for cap efficiency of messenger RNA
CN105209633A
Method for determining activity of vaccinia virus capping enzyme
CN112111558A
Method for rapidly and quantitatively detecting capping efficiency of RNA
CN112626177A
Product for detecting capping efficiency of mRNA (messenger ribonucleic acid) sample and application
CN114250268A
